Cyteir Therapeutics Stock Total Debt
CYTDelisted Stock | USD 2.76 0.01 0.36% |
Cyteir Therapeutics fundamentals help investors to digest information that contributes to Cyteir Therapeutics' financial success or failures. It also enables traders to predict the movement of Cyteir Stock. The fundamental analysis module provides a way to measure Cyteir Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cyteir Therapeutics stock.
Cyteir |
Cyteir Therapeutics Company Total Debt Analysis
Cyteir Therapeutics' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Cyteir Therapeutics Total Debt | 889 K |
Most of Cyteir Therapeutics' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cyteir Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
CompetitionBased on the latest financial disclosure, Cyteir Therapeutics has a Total Debt of 889 K. This is 99.97% lower than that of the Biotechnology sector and 99.73% lower than that of the Health Care industry. The total debt for all United States stocks is 99.98% higher than that of the company.
Cyteir Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cyteir Therapeutics' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cyteir Therapeutics could also be used in its relative valuation, which is a method of valuing Cyteir Therapeutics by comparing valuation metrics of similar companies.Cyteir Therapeutics is currently under evaluation in total debt category among its peers.
Cyteir Fundamentals
Return On Equity | -0.24 | |||
Return On Asset | -0.14 | |||
Current Valuation | (20.89 M) | |||
Shares Outstanding | 36 M | |||
Shares Owned By Insiders | 6.63 % | |||
Shares Owned By Institutions | 76.83 % | |||
Number Of Shares Shorted | 319.73 K | |||
Price To Earning | 0.36 X | |||
Price To Book | 0.87 X | |||
Gross Profit | (16.59 M) | |||
EBITDA | (33.41 M) | |||
Net Income | (33.22 M) | |||
Cash And Equivalents | 166.4 M | |||
Cash Per Share | 4.71 X | |||
Total Debt | 889 K | |||
Debt To Equity | 0.02 % | |||
Current Ratio | 19.95 X | |||
Book Value Per Share | 3.47 X | |||
Cash Flow From Operations | (25.79 M) | |||
Short Ratio | 3.07 X | |||
Earnings Per Share | (0.93) X | |||
Price To Earnings To Growth | (0.03) X | |||
Target Price | 3.0 | |||
Number Of Employees | 46 | |||
Beta | 0.096 | |||
Market Capitalization | 108.71 M | |||
Total Asset | 153.23 M | |||
Retained Earnings | (138.11 M) | |||
Working Capital | 143.89 M | |||
Current Asset | 834.8 M | |||
Current Liabilities | 366.9 M | |||
Net Asset | 153.23 M |
About Cyteir Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cyteir Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cyteir Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cyteir Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Other Consideration for investing in Cyteir Stock
If you are still planning to invest in Cyteir Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cyteir Therapeutics' history and understand the potential risks before investing.
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |